Assess whether a CMO finding is a delay or a refuse-to-file risk (bce0c4)

Situation

Clinical and Evidence Strategy work in an RWE group proposing a post-marketing study instead of a new RCT now turns on a CMO finding is because a pediatric ethicist objecting to the proposed design put scientific-advice briefing book in play. Labeling negotiator should say what scientific-advice briefing book proves.

Decision

Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMO finding is a delay / A refuse-to-file risk using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Scientific-advice briefing book reads as A CMO finding is a delay once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population.
• Scientific-advice briefing book is closer to A refuse-to-file risk after a pediatric ethicist objecting to the proposed design; A CMO finding is a delay would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in scientific-advice briefing book for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.
• Scientific-advice briefing book is missing the fact labeling negotiator needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether scientific-advice briefing book supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move a CMO finding is for labeling negotiator.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.